Teva Pharmaceutical Industries Ltd.
(NYSE: TEVA)
|
4:10 PM EST, 03/08/21 | |||
---|---|---|---|---|
Last: $10.69 | Change: +0.17 | %Change: +1.62% | Volume: 7,614,010 |
Open: | $ 10.54 | Volume: | 7,614,010 | |
---|---|---|---|---|
High: | $ 10.75 | Yield(%) | 0.00 | |
Low: | $ 10.35 | P/E Ratio (ttm): | n/a | |
Dividend ($): | 0.07 | Market Cap ($): | 11.54B | |
EPS ($) | -3.67 | Shares Out: | 1.10B |
% Price Change (last 4 weeks): | -14.05 |
---|---|
% Price Change (last 13 weeks): | 2.33 |
% Price Change (last 26 weeks): | 14.47 |
% Price Change (last 52 weeks): | 2.14 |
% Price Change (year to date): | 9.02 |
Return on Equity (%): | -33.49 |
---|---|
Return on Assets (%): | -7.43 |
Return on Invested Capital (%): | -9.43 |
Gross Profit Margin (%): | 46.38 |
---|---|
Net Profit Margin (%): | -23.95 |
Operating Profit Margin (%): | 18.36 |
|
|
50-day Moving Average: | $11.30 |
---|---|
200-day Moving Average: | $10.73 |
Avg. Daily Vol. (last 50 days): | 10,126,705 |
Avg. Daily Vol. (last 200 days): | 9,068,868 |
52-wk high: | $13.30 |
52-wk low: | $6.25 |
Bid: | $10.68 |
Ask: | $10.69 |
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
|
Teva Pharmaceutical Industries Ltd.
5 Basel Street Petach Tikva HM 4951033 Phone: 972.3.926.7267 Fax: 972.3.926.7519 http://www.teva.co.il |
Earnings (1year) ($): | -3.67 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 9.15 |
Cash Flow ($): | -2.24 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 0.63 |
Price/Book (x): | 1.05 |
Price/Cash Flow (x): | 4.00 |
Quick Ratio (x): | 0.65 |
---|---|
Current Ratio (x): | 0.99 |
LT Debt/Equity (x): | 231.50 |
Total Debt/Equity (x): | 263.30 |